Phase II Trial of Pentostatin and Targeted Busulfan as a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Using Laboratory-Guided (CD4-Guided) Immunosuppression.

Trial Profile

Phase II Trial of Pentostatin and Targeted Busulfan as a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Using Laboratory-Guided (CD4-Guided) Immunosuppression.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Pentostatin (Primary) ; Busulfan; Rituximab
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Therapeutic Use
  • Acronyms Pento & tBU
  • Most Recent Events

    • 13 Jan 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 16 Jan 2013 Planned end date changed from 1 Jul 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 20 Apr 2011 Planned End Date changed from 1 Jul 2011 to 1 Jul 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top